



Predictable and Efficient: Use Data to take the Risk Out of Site Selection

By Michelle Yu, Associate Director, Total Feasibility Services, WCG, with contribution from Priyanka Bhatt, Director, Clinical Data Scientist, WCG, and Elizabeth Lanphear, Clinical Data Analyst, WCG.

Sponsors and CROs need to reduce trial risk and increase reliability. They also need to make the most of their study start-up budget. To accomplish this, they need to select qualified sites that consistently optimize enrollment, ensure data quality, and maximize ROI.

These things are evident to anyone who's spent a day in our industry. But what's less obvious is how they find these qualified sites.

The solution: Data, wisely used. The conventional scattershot way of identifying sites is unpredictable and costly. In contrast, applying data and data analytics to the site-identification process makes the process much more predictable. Specifically, with WCG's proprietary intelligence, sponsors can predictably increase study-enrollment performance.

We've seen this with our clients, of course. But would this work on other trials?

We decided to find out.

We analyzed an actual trial--one in which we were not involved. Our analysis showed that by selecting only the top-performing sites, the Sponsor would have reduced enrollment time by six months and saved at least \$750,000.

We conducted this analysis using WCG Predict™, part of the WCG Total Feasibility™ suite. It precisely matches a study's therapeutic approach and protocol against

historical performance data from thousands of global clinical studies, investigators, and institutions by using data from the WCG Knowledge Base™.



The Analysis


To assess how WCG Predict™ could enhance study enrollment performance, we conducted a retrospective analysis of a completed type 2 diabetes trial that required 150 patients. With 44 sites, this North American trial enrolled 0.15 patients per site per month (PPSPM), and took 19 months to complete.

Using WCG Knowledge Base™ data, we conducted the retrospective analysis by identifying the top two quartiles of sites who had been successful in similar studies. Using the top 29 from this analysis, we projected enrollment at 0.24 PPSPM, shortening enrollment time from 19 months to 13 months, reducing the number of sites by 34%, and saving the Sponsor at least \$750,000 in fully loaded costs.

Actual Enrollment in Months: 19


High Performing Sites in Months: 13

6 months saved




What accounts for this? In the actual study, 62% of the sites ranked in the bottom two quartiles. In our optimized model, 100% ranked in the top two.

Before WCG Predict



After WCG Predict



Optimized and Customized

WCG Predict™ has more information about more investigators' enrollment performance than any other site-identification tool. That's because the WCG Knowledge Base™ contains validated, verifiable data on 95% of all industry-sponsored research and 85% of all FDA-regulated investigators. It also includes demographic and performance metrics for more than 140,000 investigators worldwide.

This allows us to give each client a specific, hand-tailored list of sites that are the most likely to be high enrollers for their upcoming study. In this way, WCG Predict™ delivers the best investigators, optimizes enrollment, and ensures ROI.

What it means for you

You need access to real-time data on sites and expert insights to interpret that data. That's what we provide.

WCG Predict™ can put this intelligence to work for you, helping select sites with the best recruitment potential. That translates into faster time to your next key decision point, improved ROI, and better insight into study planning timelines and milestones.

Interested? In most cases, we can match you to the right sites within 10 business days. Contact us at info@wcgclinical.com to learn more.

WCG
.....

609.945.0101

www.wcgclinical.com

